Schinazi Raymond F 4
4 · PRECISION BIOSCIENCES INC · Filed Apr 2, 2019
Insider Transaction Report
Form 4
Schinazi Raymond F
Director
Transactions
- Conversion
Convertible Promissory Note
2019-04-01→ 0 total(indirect: By RFS Partners, LP)Exercise: $13.60→ Common Stock (36,946 underlying) - Conversion
Series B Preferred Stock
2019-04-01−119,761→ 0 total(indirect: By RFS Partners, LP)→ Common Stock (56,102 underlying) - Conversion
Common Stock
2019-04-01+56,102→ 93,048 total(indirect: By RFS Partners, LP) - Conversion
Common Stock
2019-04-01$13.60/sh+36,946$502,466→ 36,946 total(indirect: By RFS Partners, LP)
Footnotes (3)
- [F1]The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein.
- [F2]The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").
- [F3]On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO.